Clinical Applications and "Proven Uses" (2026)
As of 2026, cord blood stem cells are FDA-approved and clinically established for the treatment of nearly 80 diseases. These are categorized into four primary areas:
Cancers: Including Leukemia (AML, ALL), Lymphoma, and Multiple Myeloma.
Blood Disorders: Such as Sickle Cell Anemia, Thalassemia, and Aplastic Anemia.
Immune Deficiencies: Including Severe Combined Immunodeficiency (SCID) and Wiskott-Aldrich Syndrome.
Metabolic Disorders: Such as Krabbe Disease and Hunter Syndrome.
Clinical data from 2026 indicates that transplants using a family member's cord blood have success rates twice as high as those using unrelated donors, primarily due to the higher probability of a close Human Leukocyte Antigen (HLA) match.
1 vista